Switching to dolutegravir plus lamivudine (DTG+3TC) is non-inferior to and as safe as continuing standard triple antiretroviral therapy (TAR)
JOURNAL OF THE INTERNATIONAL AIDS SOCIETY(2020)
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要
JOURNAL OF THE INTERNATIONAL AIDS SOCIETY(2020)